![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacokinetics, Dynamics, and Drug Metabolism (R.S.O., R.L.W.) and Clinical Pharmacology (K.V.), Pfizer, Inc., Groton, Connecticut
The ability to use vitro inactivation kinetic parameters in scaling to in vivo drug-drug interactions (DDIs) for mechanism-based inactivators of human cytochrome P450 (P450) enzymes was examined using eight human P450-selective marker activities in pooled human liver microsomes. These data were combined with other parameters (systemic Cmax, estimated hepatic inlet Cmax, fraction unbound, in vivo P450 enzyme degradation rate constants estimated from clinical pharmacokinetic data, and fraction of the affected drug cleared by the inhibited enzyme) to predict increases in exposure to drugs, and the predictions were compared with in vivo DDIs gathered from clinical studies reported in the scientific literature. In general, the use of unbound systemic Cmax as the inactivator concentration in vivo yielded the most accurate predictions of DDI with a mean -fold error of 1.64. Abbreviated in vitro approaches to identifying mechanism-based inactivators were developed. Testing potential inactivators at a single concentration (IC25) in a 30-min preincubation with human liver microsomes in the absence and presence of NADPH followed by assessment of P450 marker activities readily identified those compounds known to be mechanism-based inactivators and represents an approach that can be used with greater throughput. Measurement of decreases in IC50 occurring with a 30-min preincubation with liver microsomes and NADPH was also useful in identifying mechanism-based inactivators, and the IC50 measured after such a preincubation was highly correlated with the kinact/KI ratio measured after a full characterization of inactivation. Overall, these findings support the conclusion that P450 in vitro inactivation data are valuable in predicting clinical DDIs that can occur via this mechanism.
This article has been cited by other articles:
|
|
 |
|
  A. Ogasawara, I. Negishi, K. Kozakai, and T. Kume In Vivo Evaluation of Drug-Drug Interaction via Mechanism-Based Inhibition by Macrolide Antibiotics in Cynomolgus Monkeys Drug Metab. Dispos., November 1, 2009; 37(11): 2127 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-F. Krippendorff, R. Neuhaus, P. Lienau, A. Reichel, and W. Huisinga Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values J Biomol Screen, September 1, 2009; 14(8): 913 - 923. [Abstract] [PDF]
|
|
|
|
|
|
O. A. Fahmi, S. Hurst, D. Plowchalk, J. Cook, F. Guo, K. Youdim, M. Dickins, A. Phipps, A. Darekar, R. Hyland, et al. Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction Drug Metab. Dispos., August 1, 2009; 37(8): 1658 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Grimm, H. J. Einolf, S. D. Hall, K. He, H.-K. Lim, K.-H. J. Ling, C. Lu, A. A. Nomeir, E. Seibert, K. W. Skordos, et al. The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America Drug Metab. Dispos., July 1, 2009; 37(7): 1355 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shitara, Y. Nagamatsu, S. Wada, Y. Sugiyama, and T. Horie Long-Lasting Inhibition of the Transporter-Mediated Hepatic Uptake of Sulfobromophthalein by Cyclosporin A in Rats Drug Metab. Dispos., June 1, 2009; 37(6): 1172 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Stresser, A. K. Mason, E. S. Perloff, T. Ho, C. L. Crespi, A. A. Dandeneau, L. Morgan, and S. S. Dehal Differential Time- and NADPH-Dependent Inhibition of CYP2C19 by Enantiomers of Fluoxetine Drug Metab. Dispos., April 1, 2009; 37(4): 695 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Tonn, S. G. Wong, S. C. Wong, M. G. Johnson, J. Ma, R. Cho, L. C. Floren, K. Kersey, K. Berry, A. P. Marcus, et al. An Inhibitory Metabolite Leads to Dose- and Time-Dependent Pharmacokinetics of (R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in Human Subjects After Multiple Dosing Drug Metab. Dispos., March 1, 2009; 37(3): 502 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Hutzler, L. M. Balogh, M. Zientek, V. Kumar, and T. S. Tracy Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and ({+/-})-Suprofen: A Comparison of Kinetics and Probe Substrate Selection Drug Metab. Dispos., January 1, 2009; 37(1): 59 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, D. R. Jones, and S. D. Hall Prediction of the Effect of Erythromycin, Diltiazem, and Their Metabolites, Alone and in Combination, on CYP3A4 Inhibition Drug Metab. Dispos., January 1, 2009; 37(1): 150 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Bae, S. Cao, K.-A. Seo, H. Kim, M.-J. Kim, J.-H. Shon, K.-H. Liu, H.-H. Zhou, and J.-G. Shin Cytochrome P450 2B6 Catalyzes the Formation of Pharmacologically Active Sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) Metabolites in Human Liver Microsomes Drug Metab. Dispos., August 1, 2008; 36(8): 1679 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A. Fahmi, T. S. Maurer, M. Kish, E. Cardenas, S. Boldt, and D. Nettleton A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro Drug Metab. Dispos., August 1, 2008; 36(8): 1698 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Qiu, R. Zhang, J. Sun, J. A, H. Hao, Y. Peng, H. Ai, and G. Wang Inhibitory Effects of Seven Components of Danshen Extract on Catalytic Activity of Cytochrome P450 Enzyme in Human Liver Microsomes Drug Metab. Dispos., July 1, 2008; 36(7): 1308 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Bauman, K. S. Frederick, A. Sawant, R. L. Walsky, L. M. Cox, R. S. Obach, and A. S. Kalgutkar Comparison of the Bioactivation Potential of the Antidepressant and Hepatotoxin Nefazodone with Aripiprazole, a Structural Analog and Marketed Drug Drug Metab. Dispos., June 1, 2008; 36(6): 1016 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Fairman, C. Collins, and S. Chapple Progress Curve Analysis of CYP1A2 Inhibition: A More Informative Approach to the Assessment of Mechanism-Based Inactivation? Drug Metab. Dispos., December 1, 2007; 35(12): 2159 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Walsky and R. S. Obach A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1',1''-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6 Drug Metab. Dispos., November 1, 2007; 35(11): 2053 - 2059. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
